6Valkiva M. Hepatic fibrogenesis. Bratisl Lek Listy, 2002, 103:76-85.
7Reeves HL, Friedman SL. Activation of hepatic steUate cell-a key issue in liver fibrosis. Front Biosci, 2002, 7 :d808-826.
8Okazaki I, Watanabe T, Hozawa S, et al. Reversibility of hepatic fibrosis: from the first report of collagenase in the liver to the possibility of gene therapy for recovery. Keio J Med, 2001, 50: 58-65.
5Farhat BA, Marinos G, Daniels HM, et al. Evaluation of efficacy and safety of thymus humoral factor-gamma 2 in the management of chronic hepatitis B[J]. J Hepatol, 1995,23 (1): 21-27.
6Zeuzem S, Carreno V. Interleukin-12 in the treatment of chronic hepatitis B and C[J]. Antiviral Res, 2001,52 (2) : 181- 188.
7Liaw YF. Management of patients with chronic hepatitis B[J]. J Gastroenterol Hepatol, 2002,17 (4) : 406-408.
8Delaney W4h, Bartholomeusz A, Lgcarnini SA. Evoling therapies for the treatment of chronic hepatitis B virus infeetion[J]. Expert Opin Investig Drugs, 2002, 11 (2):169- 187.
9Tsai SL, Sheen IS, Chien RN, et al. Activation of Th1 immunity is a common immune mechanism for the successful treatment of hepatitis B and C: tetramer assay and therapeutic implications[J]. J Biomed Sci, 2003,10(1) : 120-135.
10Bakel DE. Adefovir dipivoxil:focus on its use in the treatment of chronic hepatitis B[J]. Rev Gastroenterol Disord, 2005,5 (2) : 89-100.
